The American Association for Cancer Research (AACR) Annual Meeting, held April 17–22, 2026, spotlighted the dynamic and rapidly advancing field of antibody-drug conjugates (ADCs) and bispecific ADCs. The event placed particular emphasis on the emergence of novel targets, next-generation payloads, and multi-functional strategies designed to overcome resistance and enhance efficacy in solid tumors.
China and the United States have emerged as global leaders in ADC development. China is rapidly closing the gap with the U.S. in both patent filings and clinical trial activity, and has become a driving force in next-generation ADC modalities such as bispecific and dual-payload constructs. With a robust and expanding pipeline, China now accounts for more than half of global next-generation ADC assets and is projected to further widen its lead in patent publications through 2026.
However, the United States remains at the forefront of innovation and clinical trial activity, though the pace of new patent filings has slowed compared to previous years. Japan is also gaining ground, with forecasts suggesting it may surpass the U.S. in new patent publications in 2026.
Meanwhile, India is establishing itself as a key manufacturing hub, leveraging contract research and development organizations (CRDMOs) to provide advanced, cost-effective bioconjugation capabilities.
Europe continues to play a strong role, particularly in contract manufacturing and early-stage development, with specialized centers in Switzerland and other countries.
Key trends for 2026 include rapid clinical advancement, increased investment in ADCs for oncology, and a surge in accelerated regulatory approvals. In this article—the first in a three-part series—we summarize some of the most significant preclinical and early clinical advances presented at AACR 2026, highlighting the growing momentum and global innovation driving ADC development in oncology.
Novel ADCs Targeting the Tumor Microenvironment and Immune Evasion
MERTK-Targeting ADC (RGX-019-MMAE)
RGX-019-MMAE is a new preclinical ADC targeting myeloid epithelial reproductive tyrosine kinase (MERTK), a receptor tyrosine kinase highly expressed on immunosuppressive M2 tumor-associated macrophages (TAMs) and certain cancer cells, and is associated with poor prognosis. MERTK is overexpressed in acute myeloid leukemia (AML) and could serve as a therapeutic target. The investigational agent was developed by Inspirna by conjugating the monoclonal antibody RGX-019 to monomethyl auristatin E (MMAE) on an average drug-to-antibody ratio (DAR) of 4, via a protease-cleavable linker with a PEG spacer for site-specific cysteine conjugation. This ADC simultaneously depletes M2 TAMs and directly kills MERTK-expressing tumor cells. [1][2]
Preclinical studies demonstrated potent tumor growth inhibition, depletion of M2 macrophages, and no observed retinal toxicity—a common side effect of other MERTK-targeted agents. These findings support the dual targeting of cancer cells and the immunosuppressive microenvironment as a promising therapeutic strategy. [][]
Bispecific and Dual-Targeting ADCs: Expanding the Therapeutic Window
JS212 (EGFR/HER3 Bispecific ADC)
In a first-in-human trial, JS212, an exatecan-conjugated recombinant humanized bispecific ADC targeting both EGFR and HER3, demonstrated encouraging response rates (ORR up to 45.5% in esophageal cancer and 37.5% in HR+/HER2- breast cancer) and manageable toxicity in heavily pretreated patients with advanced solid tumors, including non-small-cell lung cancer [NSCLC], breast cancer, and esophageal squamous carcinoma [ESCC]. This study, which showed encouraging antitumor activity across a range of dose levels and multiple solid tumor types with a tolerable safety profile, highlights the potential of dual-targeting ADCs to overcome pathway redundancy and resistance mechanisms in cancers driven by EGFR and HER3.
JS212 is being developed by Shanghai Junshi Biosciences Co. The China National Medical Products Administration (NMPA) approved the Investigational New Drug (IND) application for JS212 in March 2025, followed by FDA IND clearance in December 2025. [3]
ACR335 (cMET/EGFR Bispecific Dual-Payload ADC)
cMET and EGFR are frequently co-expressed oncogenic drivers in solid tumors, with pathway crosstalk driving therapeutic resistance. Preclinical data on ACR335, a first-in-class bispecific ADC that site-specifically conjugates IBR335, a cMET and EGFR-targeting antibody, with a dual topoisomerase I (Top1) inhibitor and a non-top/non-tubulin inhibitor payload (DAR 4+4), revealed potent and broad antitumor activity across multiple models, efficient internalization, and a favorable safety profile. By simultaneously inhibiting two oncogenic pathways and delivering two distinct cytotoxins, ACR335 aims to maximize efficacy and delay resistance.
The novel ADC is developed by researchers affiliated with Tavotek Biotherapeutics, using the MuSC™ (Multifunctional Site-specific Conjugation) platform developed by Adcoris. Phase I clinical trials are expected to start in Q2 2026.[4]
BH4601 (PD-L1/B7H3 Bispecific ADC)
This tetravalent ADC targets both PD-L1 and B7-H3, immune checkpoint molecules that are members of the B7 superfamily, which are frequently overexpressed across various tumor types. Targeting either PD-L1 or B7-H3 individually has demonstrated modest clinical efficacy. However, the co-expression of PD-L1 and B7-H3 in multiple malignancies offers a compelling rationale for dual-targeting strategies. Such a bispecific approach broadens the scope of tumor targeting and simultaneously alleviates T-cell suppression. Preclinical studies have demonstrated that by simultaneously engaging the PD-L1 and B7H3 pathways, BH4601 achieves robust T-cell activation, efficient tumor cell killing, and, compared to parental ADCs, improved therapeutic efficacy. Based on these observations, the researchers believe that these outcomes support further development of this dual immune checkpoint-targeting ADC.
BH4601 is being developed by Beijing Hanmi Pharmaceutical, Hanmi Group’s China subsidiary.[5]
First-in-Human and Early Clinical Data for Next-Generation ADCs
ZW191 (Folate Receptor α-Targeted ADC)
ZW191, being developed by Zymeworks, is an ADC targeting the clinically validated human folate receptor α (FRα), which showed a 52% objective response rate (ORR) in heavily pretreated patients with ovarian and endometrial cancers, with responses observed regardless of FRα expression level. The agent was well tolerated and is progressing to dose optimization/expansion phases.
ZW191 is a fully humanized IgG1 antibody conjugated to ZD06519, a novel, proprietary, moderately potent topoisomerase I inhibitor (TOPO1i) payload, via a stable, protease-cleavable linker, combining a maleimidocaproyl (MC) anchor with a GGFG- (Gly-Gly-Phe-Gly) tetrapeptide sequence to connect a FRα-targeting antibody. The GGFG- peptide sequence is specifically designed to be cleaved by lysosomal proteases (such as Cathepsin B) after the ADC is internalized into the tumor cell, while the maleimidocaproyl anchor covalently conjugates to the antibody’s endogenous interchain cysteines, ensuring structural stability. ZW191 is designed for high internalization and features a ‘bystander effect,’ allowing ‘freed’ payload to cross cell membranes and kill neighboring tumor cells even when they express low FRα.
In preclinical studies using patient-derived xenograft models of ovarian cancer, endometrial cancer, NSCLC, and TNBC, ZW191 demonstrated favorable efficacy and tolerability, with a notable improvement over mirvetuximab soravtansine (Elahere®; AbbVie).
In the ongoing 2-part, phase 1 study (NCT06555744) in a heavily pretreated population of 51 patients with ovarian cancer, endometrial cancer, or non-small cell lung cancer, ZW191 demonstrated compelling efficacy (regardless of FRα expression) and a favorable safety profile. Dose levels of 6.4 and 9.6 mg/kg Q3W are now being evaluated in the Part 2a dose optimization phase of the study. [6][7]
ACR246 (Anti-5T4 ADC)
ACR246, targeting the oncofetal antigen 5T4, displayed a manageable safety profile and a 35% ORR in advanced solid tumors, with higher response rates (46%) in the optimal dose range. Disease control rates exceeded 90% in biomarker-positive subgroups, and pharmacokinetic analyses confirmed linker stability, supporting ongoing clinical evaluation.
The investigational agent. being developed by Hangzhou Adcoris Biopharma Co, is a humanized monoclonal antibody directed against 5T4, which has limited expression in normal adult tissues but high expression in many solid tumors, including esophageal squamous cell carcinoma, gastric cancer, ovarian cancer, colorectal cancer, and non-small cell lung cancer. It is site-specifically conjugated, via a stable, cleavable linker, to the cell-penetrating cytotoxic agent and DNA topoisomerase I inhibitor D-2102 with a drug-to-antibody ratio (DAR) of 8.
In the ongoing phase 1 study (NCT06238401) ACR246 demonstrates a manageable safety profile and promising anti-tumor activity in heavily pretreated patients with advanced solid tumors.[8]
Expanding the ADC Target Universe: New Targets and Payloads
MK-3120 (Nectin-4 ADC)
Preclinical studies of MK-3120 (SKB410), a nectin-4-directed ADC with a unique, bifunctional linker that maximizes payload delivery to tumor cells both through its irreversible connection with a novel anti-nectin-4 monoclonal antibody and pH-sensitive cleavage from a belotecan-derived topo I inhibitor payload in the lysosome, demonstrated a distinct responder population compared to the monomethyl auristatin E (MMAE)-based enfortumab vedotin, underscoring the importance of payload and linker chemistry for ADC activity. MK-3120 is being developed by Merck & Co/MSD in collaboration with Sichuan Kelun-Biotech Biopharmaceutical.[9]
HP-004 (ALPP/ALPPL2 ADC)
Alkaline phosphatase placental (ALPP) and ALP-like 2 (ALPPL2) are highly expressed in a wide range of solid tumors, including ovarian, endometrial, gastric, and non-small cell lung cancer (NSCLC). However, their expression is limited in normal or healthy tissues, making ALPP/ALPPL2 attractive targets for an ADC. HP-004 is a highly selective and efficient ALPP/ALPPL2-targeting ADC, site-specifically conjugated with monomethyl auristatin E (MMAE) with an average DAR of about 4, that has shown robust tumor regression and is being further explored in bispecific ADC formats. The investigative ADC is being developed by Suzhou Hepius Therapeutics Co. [10]
DB-1329 (CDCP1-Targeting ADC)
AI-powered multi-omics identified CDCP1, a protein overexpressed in various solid tumors, as a promising ADC target across multiple solid tumors. DB-1329, developed by DualityBio, comprises a fully human anti-CDCP1 monoclonal antibody with high affinity and specificity, conjugated via a protease-cleavable linker to a potent camptothecin-based TOP1 inhibitor payload. The investigational drug exhibited rapid and efficient internalization upon binding to CDCP1 and has demonstrated durable tumor regression and a favorable safety profile in preclinical models.
DB-1329 also displayed a favorable pharmacokinetic profile, was well-tolerated in toxicology studies, and exhibited a manageable safety profile, supporting its advancement. [11]
XNW28012 (Tissue Factor ADC)
XNW28012 is a Tissue Factor-targeting ADC comprised of a humanized IgG1 antibody conjugated with a potent DNA topoisomerase I inhibitor via a protease-cleavable linker with a drug-antibody ratio (DAR) of 8. The tripeptide linker is highly stable in blood and cleavable in the tumor microenvironment and in tumor cell lysosomes. Tissue factor is a transmembrane protein that serves as the primary initiator of physiological hemostasis, binds coagulation factor VII (FVII), promotes its activation, and enhances the proteolytic activity of FVIIa to initiate the extrinsic pathway of blood coagulation.
The investigational ADC, being developed by Evopoint Biosciences, is currently in phase 1/2 (NCT06799637; CTR20233056) and Phase 3 clinical trials (CTR20252545).[12]
XNW27011 (Claudin18.2 ADC)
XNW27011 is an ADC composed of a monoclonal antibody targeting CLDN18.2 with a novel topoisomerase 1inhibitor (topo1i) (payload, YL0010014) site-specifically conjugated via a cleavable linker with a drug-antibody ratio (DAR) of 8.
The investigational agent, being developed by Evopoint Biosciences for the treatment of patients with various CLDN 18.2-positive solid tumors, including gastric cancers and pancreatic cancers, in China, demonstrated high specificity, robust antitumor activity, and manageable safety in preclinical models of various solid tumors. XNW27011 is currently under evaluation in a phase 3 trial (CTR20252730).[13]
LM-338 (Anti-STn ADC)
This innovative ADC, developed by LaNova Medicines in collaboration with Sino Biopharmaceutical, targets the Sialyl-Thomsen-nouveau antigen (STn or Sialyl-Tn, also known as CD175s)*, which is rarely seen in normal or healthy adult tissues but is highly expressed in many types of solid tumors, including ovarian, breast, bladder, cervical, colon, pancreatic, and lung cancers. [14] STn is a disaccharide, a carbohydrate formed when two monosaccharides (or simple sugars) join together via a glycosidic linkage through a dehydration reaction, formed when the enzyme ST6GalNAc-I (STn synthase) adds a sialic acid residue to the GalNAcα-O-Ser/Thr (Tn antigen). This acts as a terminal ‘cap,’ stopping further extension of the O-glycan chain and preventing the formation of more complex carbohydrate structures.
The Sialyl-Thomsen-nouveau antigen acts as a tumor-associated carbohydrate antigen (TACA), which helps cancer cells evade the immune system by interacting with inhibitory receptors on immune cells (such as Siglecs) and by inhibiting mature immune cell function. Its presence on cell-surface (tethered) mucins (such as MUC1) reduces cell-cell adhesion, thereby promoting tumor cell migration, invasion, and metastatic potential. As a result, STn is correlated with cancer progression and poor prognosis and is associated with an immunosuppressive microenvironment. Furthermore, considered an early marker of cancer, STn is a valuable target in cancer therapy. [15][16]
The investigational ADC, LM-338, comprises a humanized monoclonal antibody (LM-138) site-specifically conjugated to a topoisomerase I inhibitor via a highly stable, cleavable linker, with a drug-antibody ratio of 4. In preclinical studies, it delivered potent cytotoxic and bystander effects in multiple models and was well tolerated up to 60 mg/kg in non-human primates. In preclinical studies, LM-338 demonstrated promising results, including high target specificity, minimal cross-reactivity to structural analogs, and significant antitumor activity in both cell line-derived xenograft (CDX) and patient-derived xenograft (PDX) models. It is being developed to address resistance in traditional cancer therapies, particularly in tumors with high STn expression. [17]
IN30758 (Integrin-Targeted ADC)
IN30758, a novel ADC being developed by InxMed (Ying Shi Bio), targets integrins such as alphaVbeta6, an epithelial-specific transmembrane receptor that is typically absent in healthy adult tissues but significantly upregulated during wound healing, chronic inflammation, and in various solid epithelial cancers, including pancreatic ductal adenocarcinoma (PDAC), non-small cell lung cancer (NSCLC), and ovarian cancer. It plays a major role in cancer progression, promoting tumor cell migration, modulating invasion, regulating the expression of matrix metalloproteases (MMPs), and activating TGF-β1. [18]
IN30758 comprises an integrin antibody (A28) and a clinically validated linker payload (LD38) and has demonstrated strong preclinical efficacy across a range of solid tumors in both cell line-derived xenograft (CDX) and patient-derived xenograft (PDX) models, including DXD-resistant tumor models. As an ADC candidate, IN30758 exhibits several advantages over current treatment options. Its proprietary linker–topoisomerase inhibitor payload system is designed to enhance stability and efficacy while effectively countering drug resistance. The molecule has demonstrated robust preclinical efficacy across a range of cancer models, highlighting its broad utility. Furthermore, IN30758 has shown a wide therapeutic window and a favorable safety profile in non‑human primate studies. Based on these outcomes, IN30758 is progressing toward clinical development. [19]
ANT045 (Antibody Fragment Drug Conjugate for cMET)
A novel antibody fragment drug conjugate (FDC), ANT045, targeting cMET, achieved high drug-to-antibody ratios and showed efficacy in diverse cMET-expressing tumors, with improved safety and pharmacokinetics. FDCs are an emerging class of targeted therapies that use small-format antibody fragments, such as Fab, scFv, or VHH, instead of full-length antibodies (∼150 kDa), thereby enabling better tissue penetration. In preclinical studies, these novel format conjugates also demonstrated faster, safer systemic clearance and higher Drug-to-Antibody Ratios (DARs). They exhibit potent anti-tumor efficacy in cancer cells with elevated cMET expression, potentially overcoming some of the challenges posed by other therapeutic classes.
ANT045 is developed by Antikor Biopharma for the treatment of solid tumors, particularly gastrointestinal cancers. ANT-045 demonstrated superior tumor cure efficacy in cMET-high, moderate, and low CDX and PDX gastric cancer xenograft models and better tolerability than the comparator ADC telisotuzumab vedotin (Emrelis®; AbbVie). Furthermore, in a non-GLP, non-human primate study, the investigational agent was well tolerated with a predicted half-life in humans of around 12-14 hours, supporting a viable clinical dosing strategy with a wide therapeutic window.[20]
GENA-104 / EP0089 (CNTN4-Targeted ADC)
Contactin 4 (CNTN4), also known as BIG-2, a glycosylphosphatidylinositol (GPI)-anchored neuronal adhesion molecule that has recently been identified as a novel immune checkpoint protein. It is involved in synapse formation, axonal growth, and guidance, and is highly expressed in the brain. Recent studies have shown that CNTN4 is overexpressed in solid tumors, including gastric cancer, hepatocellular cancer, and pancreatic cancer. It suppresses antitumor T-cell activity by binding to Amyloid Precursor Protein (APP) on T cells, disrupting their function. High CNTN4 expression correlates with poor prognosis and low PD-L1 levels, making it a promising, potentially complementary target for immunotherapy.[21]
In preclinical studies, GENA-104 (also known as EP0089), a first-in-class immuno-oncology agent designed to target CNTN4, originally developed by South Korean Genome and Company, was in-licensed by Ellipses Pharma and demonstrated potent cytotoxicity, immunogenic cell death, and strong in vivo efficacy, particularly in sarcoma and hepatocellular carcinoma models. GENA-104 consists of GENA-104A16.hIgG1, an anti-CNTN4 antibody engineered with reduced effector function, conjugated via cysteine to a hydrophilic, cleavable linker which is designed to minimize retro-Michael elimination. The payload is exatecan, a potent topoisomerase I inhibitor, incorporated at a high drug-to-antibody (DAR) ratio. A Phase 1 Investigational New Drug (IND) application was approved in South Korea in January 2024, and a first-in-human Phase 1 study is ongoing. [21][22]
ZL-6201 (LRRC15-Targeting ADC)
Leucine-rich repeat-containing protein 15 (LRRC15), a transmembrane protein involved in cell-cell and cell-extracellular matrix interactions, is overexpressed in tumors of mesenchymal origin, including sarcomas, glioblastoma, and melanoma, where its expression has been implicated in promoting metastasis. LRRC15 is also upregulated in cancer-associated fibroblasts (CAFs) found in the tumor microenvironment (TME) of multiple epithelial tumors. The high expression in tumors and CAFs, but the minimal or non-expression in normal or healthy cells, makes LRRC15 a potentially effective therapeutic target.
ZL-6201, a novel ADC being developed by Zai Lab in collaboration with MediLink Therapeutics, demonstrated tumor and CAF targeting, bystander killing, and strong efficacy, supporting ongoing clinical development. The investigational agent was built on the tumor microenvironment-activable linker-payload (TMALIN®) platform, with an irreversible pyrimidine-coupling anchor and a valyl dipropyl-lysyl glycinamide-methylene (-VK*G-NHCH2-O-) cleavable sequence. The platform features a high hydrophilicity linker-payload and remarkable stability in circulation and is designed to enhance the therapeutic index and reduce off-target payload toxicity.
ZL-6201 comprises a humanized anti-LRRC15 antibody, a hydrophilic protease-cleavable linker, and C24, a novel camptothecin-derived topoisomerase I inhibitor payload site-specifically conjugated with an average drug-to-antibody ratio (DAR) of 8. Preclinical studies have demonstrated that ZL-6201 effectively reduces tumor growth and is designed to overcome standard limitations, such as high toxicity observed in some other ADCs. As of early 2026, a Phase 1 study is ongoing.[23]
3H-10000 (FGFR2b-Targeted Vedotin ADC)
Overexpression of fibroblast growth factor receptor 2 IIIb (FGFR2b) across multiple cancer types promotes dysregulated tyrosine kinase activation and results in tumor progression and unchecked malignancy. 3H-10000 is an investigational ADC targeting FGFR2b. The novel ADC is being developed by 3H (Shanghai) Pharmaceuticals and comprises a specific anti-FGFR2b human monoclonal antibody conjugated to the cytotoxic payload monomethyl auristatin E (MMAE) via a protease-cleavable maleimidocaproyl valine citrulline (mc-vc) linker.
In preclinical studies, 3H-10000, in combination with the FGFR2 selective inhibitor 3HP-2827, demonstrated potent activity in gastric and NSCLC models and was well tolerated in animal studies. An active phase 1/2 clinical trial (NCT07354711 and CTR20254555) is underway to evaluate the safety, efficacy, and pharmacokinetics of 3H-10000 in patients with unresectable or metastatic advanced solid tumors.[24]
Innovations in ADC Biomarker Assessment and Tumor Modeling
- Hybrid Spatial Multi-Omics Platform.
- The spatial organization of tumor cells, immune infiltrates, and the surrounding stroma—reflected in both protein expression and gene transcription—plays a pivotal role in determining therapeutic response and prognosis. Conventional spatial profiling methods often rely on serial tissue sections, which can compromise precise cellular co-localization, or involve harsh processing steps that risk damaging target biomolecules. To address these limitations, a collaborative effort between Bio-Techne’s Advanced Cell Diagnostics (ACD) and Ultivue (now part of Vizgen) has led to the development of a novel hybrid integrated workflow combining Ultivue’s InSituPlex technology with ACD’s protease-free RNAscope™ in situ hybridization (ISH), high-throughput, single-slide co-localization of protein and RNA biomarkers, facilitating spatial phenotyping and improved patient stratification. This innovative approach enables simultaneous detection of RNA and protein biomarkers on the same tissue slide, preserving target integrity and enabling high-fidelity, multiplexed spatial analysis. [25]
- Patient-Derived Organoid (PDO) Platforms:
- Patient-derived organoids (PDOs), generated ex vivo and in vitro, are increasingly used for therapeutic screening because they better replicate physiological conditions than traditional cell lines. Despite their promise, significant challenges remain to fully harness PDOs for drug discovery and development. The integration of automated PDO co-culture systems—featuring heterogeneous target expression—enables detailed analysis of antibody-drug conjugate (ADC) bystander effects, facilitating improved ADC design and precision biomarker approaches. When combined with automated culturing and advanced image analysis, PDO-based platforms offer a powerful means to study ADC bystander effects within heterogeneous tumor environments. Insights gained from these systems will help shape future ADC development and guide biomarker-driven patient selection strategies.
[26][27]
- Patient-derived organoids (PDOs), generated ex vivo and in vitro, are increasingly used for therapeutic screening because they better replicate physiological conditions than traditional cell lines. Despite their promise, significant challenges remain to fully harness PDOs for drug discovery and development. The integration of automated PDO co-culture systems—featuring heterogeneous target expression—enables detailed analysis of antibody-drug conjugate (ADC) bystander effects, facilitating improved ADC design and precision biomarker approaches. When combined with automated culturing and advanced image analysis, PDO-based platforms offer a powerful means to study ADC bystander effects within heterogeneous tumor environments. Insights gained from these systems will help shape future ADC development and guide biomarker-driven patient selection strategies.
Future Directions
The AACR 2026 annual meeting highlights the rapid evolution of ADC technology, with advances in target selection, dual-targeting strategies, novel payloads, and companion biomarker platforms.
Next-generation ADCs and bispecific ADCs are demonstrating the potential to overcome resistance, target the tumor microenvironment, and deliver durable responses across a broad spectrum of solid tumors. Ongoing and upcoming clinical trials will further define their role in the future of precision oncology.
__
Clinical trials
JS212 Combination Therapies in Metastatic Colorectal Cancer – ClinicalTrials.gov ID NCT07503756
A Phase II Clinical Study Evaluating the Combination Therapy of JS212 in Patients With Advanced Lung Cancer – ClinicalTrials.gov ID NCT07309276
JS212 Plus JS111 in EGFR-Mutant Advanced NSCLC: A Phase II Study – ClinicalTrials.gov ID NCT07518160
Phase II Study of JS212/JS213 as Monotherapy and in Combination in Patients With Advanced Malignant Solid Tumors – ClinicalTrials.gov ID NCT07480733
A Study Evaluating the Safety and Efficacy of JS212 Combination Therapy in Patients With Advanced Esophageal Squamous Cell Carcinoma – ClinicalTrials.gov ID NCT07484724
A Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Initial Efficacy of JS212 in Subjects With Advanced Malignant Solid Tumour – ClinicalTrials.gov ID NCT06888830
A Study of ZW191 in Participants With Solid Tumors – ClinicalTrials.gov ID NCT06555744
An Open-label, Multi-center, Dose-escalation and Cohort Expansion Phase I/IIa Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile and Efficacy of ACR246 in Patients With Advanced Solid Tumors – ClinicalTrials.gov ID NCT06238401
A Clinical Study of MK-3120 in People With Bladder Cancer (MK-3120-003) – ClinicalTrials.gov ID NCT07222488
A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002) – ClinicalTrials.gov ID NCT06818643
Study of XNW28012 in Subjects With Advanced Solid Tumors Who Failed Standard Treatments – ClinicalTrials.gov ID NCT06799637
XNW27011 Study of Advanced Solid Tumor Subjects Who Failed Standard Therapies – ClinicalTrials.gov ID NCT06792435
A First-in-human Study of GENA-104A16 in Patients With Advanced Solid Tumors – ClinicalTrials.gov ID NCT06235541
A Study to Evaluate the Safety and Tolerability of EP0089 – ClinicalTrials.gov ID NCT07030478
Phase 1a/b Study of ZL-6201 Safety, PK, and Preliminary Efficacy in Sarcoma and Selected Tumors – ClinicalTrials.gov ID NCT07374848
A First-in-human Study of 3H-10000 in Patients With Unresectable or Metastatic Solid Tumors – ClinicalTrials.gov ID NCT07354711
Highlights of Prescribing Information
Mirvetuximab soravtansine (Elahere®; AbbVie)[Prescribing Information]
Telisotuzumab vedotin (Emrelis®; AbbVie)[Prescribing Information]
Reference
[1] Tyagi A, Siddiqui M, Eckstrom A, Kurth I, Takeda S, Sharma P, Borthakur G, Yuan B, Abbas HA, Anand V, Borgman J, Kornblau S, Maiti A, Battula VL. RGX-019-MMAE inhibits leukemia progression by targeting MER proto-oncogene tyrosine kinase (MERTK) in acute myeloid leukemia. J Exp Clin Cancer Res. 2026 Mar 28;45(1):81. doi: 10.1186/s13046-026-03657-y. PMID: 41896977; PMCID: PMC13032267.
[2] Anudishi Tyagi, Maryam Siddiqui, Isabel Kurth, Shugaku Takeda, Amanda Eckstrom, Jenny Borgman, Abhishek Maiti, Venkata Lokesh Battula. Targeting myeloid epithelial tyrosine kinase (MERTK) receptor in acute myeloid leukemia using a novel antibody-drug conjugate, RGX-019-MMAE [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 6341.
[3] Shun Lu, Huiping Li, Yinghua Ji, Longhua Sun, Zhangzhou Huang, Huangming Hong, Jianhua Shi, Fangling Ning, Yongmei Yin, Jian Fang, Aobing Bai, Dexuan Zhang, Zhihao Jiang, Qing Yang. Preliminary results from a first-in-human phase I/II study of JS212, an EGFR/HER3-targeted bispecific antibody-drug conjugate (ADC), in patients with advanced solid tumors [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 2 (Late-Breaking, Clinical Trial, and Invited Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(8_Suppl):Abstract nr CT128.
[4] Zhenwei Miao, Feng Wang, Shanwei Weng, Li Yang, Wu Yao. ACR335, a novel cMET/EGFR bispecific dual-payload antibody-drug conjugate, demonstrates potent and broad antitumor activity in preclinical models of solid tumors [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 1775.
[5] Jun Wang, Pengfei Rong, Jing Wang, Yang Liu, Mengrui Zhao, Jie Feng, Lijuan Li, Yue Wang, Aihong Zhang, Dongyang Li, Hongjuan Zhang, Jingmei Cai, Xiaochun Li, Jiangcheng Xu, Jiawang Liu, Hui Ding, Fangxing Ouyang, Kyoungwoo Lee. Preclinical evaluation of BH4601, a novel tetravalent PD-L1 and B7H3 bispecific antibody-drug conjugate (ADC) with Topo1 inhibitor for the treatment of solid tumors [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 5756.
[6] Lawn S, Hernandez Rojas A, Wong J, Degefie L, Sagoe-Wagner A, Wu A, Bissessur A, Bonderud M, Wu K, Alonzo D, Das S, Chan P, Fung V, Yang L, Winters GC, Stahl K, Urosev D, Frantzen K, Moore PA, Colombo R, Barnscher SD, Rich JR. ZW191, a FRα-targeted topoisomerase 1 inhibitor ADC with a differentiated antitumor efficacy and tolerability profile. Clin Cancer Res. 2026 Apr 20. doi: 10.1158/1078-0432.CCR-25-4691. Epub ahead of print. PMID: 42007996.
[7] Patricia LoRusso, David Sommerhalder, Kosei Hasegawa, Kenichi Harano, David S. Tan, Noboru Yamamoto, David M. O’Malley, Kathleen N. Moore, Sarah E. Church, Lin Lu, Sabeen Mekan, Pranshul Chauha, Jung-Yun Lee. Phase 1 first-in-human multicenter open-label study of ZW191, a folate receptor α (FRα)-targeting antibody-drug conjugate (ADC), in patients with advanced solid tumors: Part 1 dose-escalation results [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 2 (Late-Breaking, Clinical Trial, and Invited Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(8_Suppl):Abstract nr CT306.
[8] Panpan Zhang, Yuping Sun, Zhengbo Song, Zhenwei Miao, Lina Chen, Feng Wang, Yang Li, Lin Shen. ACR246, a novel anti-5T4 antibody-drug conjugate: Updated phase I/IIa study results in advanced solid tumors [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 2 (Late-Breaking, Clinical Trial, and Invited Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(8_Suppl):Abstract nr CT049.
[9] Evan Barry, Amy Beebe, Razvan Cristescu, Qingyun Yan, Mingmei Cai, Konstantin Dobrenkov, Gustave Hebert, Douglas Linn, Alan Northrup, Amir Vajdi, Brian Long. Preclinical evaluation of the nectin-4 antibody-drug conjugate MK-3120 (SKB410) in a panel of solid-tumor patient-derived xenograft models [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 2 (Late-Breaking, Clinical Trial, and Invited Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(8_Suppl):Abstract nr LB490.
[10] Yujun Huang, Xiao Liang, Yajuan Xue. A novel antibody-drug conjugate targeting alkaline phosphatases ALPP and ALPPL2 in solid tumors [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 4401.
[11] Hui Yang, Yujie Liu, Yang Qiu, Haiqing Hua. DB-1329: A novel antibody-drug conjugate targeting CDCP1 demonstrates potent preclinical anti-tumor activity across multiple solid tumors [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 2656.
[12] Yonghan Hu, Zhe Zhang, Yuanbao Li, Liang Kong, Shihua Wang, Zhenwei Wu, Xiaocheng Hu, Ka Ruan, Wengui Wang, Guorong Li, Qifeng Shi, Haiyang Wei, Xiaojun Liu, Meijie Le, Jing Qiang. Preclinical development of XNW28012, an antibody drug conjugate targeting tissue factor for treatment of solid tumors [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 4437.
[13] Yonghan Hu, Yuanbao Li, Zhenwei Wu, Yuzhen Hou, Liang Kong, Shihua Wang, Zhe Zhang, Ka Ruan, Wengui Wang, Hui Zhao, Qifeng Shi, Haiyang Wei, Xiaojun Liu, Meijie Le, Jing Qiang. Preclinical development of XNW27011, an antibody drug conjugate targeting claudin18.2 for treatment of CLDN 18.2-positive solid tumors [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 1690.
[14] Prendergast JM, Galvao da Silva AP, Eavarone DA, Ghaderi D, Zhang M, Brady D, Wicks J, DeSander J, Behrens J, Rueda BR. Novel anti-Sialyl-Tn monoclonal antibodies and antibody-drug conjugates demonstrate tumor specificity and anti-tumor activity. MAbs. 2017 May/Jun;9(4):615-627. doi: 10.1080/19420862.2017.1290752. Epub 2017 Feb 22. PMID: 28281872; PMCID: PMC5419082.
[15] Julien S, Videira PA, Delannoy P. Sialyl-tn in cancer: (how) did we miss the target? Biomolecules. 2012 Oct 11;2(4):435-66. doi: 10.3390/biom2040435. PMID: 24970145; PMCID: PMC4030860.
[16] Loureiro LR, Carrascal MA, Barbas A, Ramalho JS, Novo C, Delannoy P, Videira PA. Challenges in Antibody Development against Tn and Sialyl-Tn Antigens. Biomolecules. 2015 Aug 11;5(3):1783-809. doi: 10.3390/biom5031783. PMID: 26270678; PMCID: PMC4598775.
[17] Jin Li, Junwei Yang, Yuan Li, Te Du, Xia Qin, Da Fei, Lei Shi, Wei Cao. Preclinical evaluation of LM-338: An innovative anti-STn antibody drug conjugate for solid tumors [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 5636.
[18] Bandyopadhyay A, Raghavan S. Defining the role of integrin alphavbeta6 in cancer. Curr Drug Targets. 2009 Jul;10(7):645-52. doi: 10.2174/138945009788680374. PMID: 19601768; PMCID: PMC2888263.
[19] Baoyuan Zhang, Shiqiang Lu, Yue Ma, Jiaming Gao, Fengmin Xi, Ran Pang, Leo Liu, Zaiqi Wang, . IN30758, an integrin-targeted antibody drug conjugate (ADC) demonstrating strong therapeutic effects in multiple solid tumors [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 1696.
[20] Mahendra Deonarain, Bryan Edwards, Gokhan Yahioglu, Isabel Perez-Castro, Sam Ness, Anja Pomowski, Laura Bouché, Soraya Diez-Posada, Lowri Davies, Howard Desmond. ANT045: A novel format, antibody fragment drug-conjugate (FDC) product for challenging cMET-expressing solid tumors [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 4399.
[21] Jeon BN, Kim S, Kim Y, Yu H, Park C, Kim G, Ha Y, Kim GY, Kim H, Palucka KA, Lee C, Cha M, Park H. Contactin-4 suppresses antitumor T cell responses by engaging amyloid precursor protein. Sci Immunol. 2024 Oct 11;9(100):eadk7237. doi: 10.1126/sciimmunol.adk7237. Epub 2024 Oct 11. PMID: 39392894.
[22] Mi Young Cha, Hyunkyung Yu, Hyunuk Kim, Kitae Park, Youngeun Ha, Seungmin Byun, Jiyeong Lee, Mira Kim, Bu-Nam Jeon, Soojung Moon, Gyeongyeon Kim, Gyeong-Jin Cheon, Hansoo Park. Preclinical development of GENA-104 ADC, an exatecan-based novel antibody-drug conjugate targeting CNTN4, for solid tumors [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl): Abstract nr 4443.
[23] He Xu, Zengxia Li, Jiaqing Yi, Wilson Peng, Qiuping Ye, Xinchao Xia, Lei Wang, Xinchuan Dai, Yue Ge, Donghui Li, Ziruo Wen, Changwei Lv, Joshua Zeng, Qidong Hu, Lina Wang, Jelveh Lameh, Nathan Ihle, Bing Wan, Linda N. Liu. Discovery of ZL-6201, a novel LRRC15-targeting antibody drug conjugate (ADC) for the treatment of sarcomas and epithelial solid tumors [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 2399.
[24] Mingming Gao, Susan Liuchen, Jufang Lin, Bingshuang Xu, Yan Ding, Qiaoxin Zeng, Zhixiong Zhang, Li Cao, Chunzhe Guo, Tao Liu, Ning Jiao, Yong Peng, Shaojing Hu. Preclinical development of 3H-10000, a novel vedotin antibody-drug conjugate for treatment of FGFR2b-expressing cancers [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 2 (Late-Breaking, Clinical Trial, and Invited Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(8_Suppl):Abstract nr LB268.
[25] Patrick Savickas, AKASH PARVATIKAR, Jack Casey, Anushka Dikshit, AMAN TYAGI. Rapid antibody drug conjugate markers and RNA biomarkers in solid tumors using a hybrid Ultivue InSituPlex and Protease-Free RNAscope Workflow [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 3971.
[26] Oksana Sirenko, Nikki Carter. Leveraging patient-derived organoids to investigate bystander effects of antibody-drug conjugates in solid tumor backgrounds [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 4397.
[27] Xiaolong Tu, Likun Zhang, Jie Lin, Hengyuan Liu, Jun Zhou, Marrit Putker, Ludovic Bourre, Julie Myer. Integrated multi-omics analysis reveals conserved tumor-associated antigens (TAAs) profiles in PDX and organoid models for advancing ADC development [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 7540.
[28] Daniele Mori, Javier Frias Aldeguer, Rene Overmeer, Sylvia F. Boj, . An image-based approach to visualize ADC internalization and cytotoxicity in patient-derived organoids [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 5702.
Featured image: Poster session during the 2019 Annual Meeting of the American Association for Cancer Research. Photo courtesy © AACR/Todd Buchanan. Used with permission.
DOI
